asa glp 1 agonist guidelines A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia GLP-1 receptor agonists and next-generation
Description
The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.

hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12)

How GLP-1 and GIP pathways work, why dual-action tirzepatide (Mounjaro) differs from GLP-1-only medicines, and what trial averages mean for UK patients.
Those who took Ozempic or a similar drug had a 40% lower chance of overdosing on opioids and a 50% lower chance of getting drunk compared to those who didn't take the medication, the study found.

GIP Receptor Antagonism (Blocking): Unlike many dual-agonists that activate GIP, MariTide blocks it
The surprising science and sobering risks revealed.
